Sign inCreate account

Report workspace tools

NCT02527746COMPLETEDanonymous

A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast Cancer

Sponsor

Source record

EVIVE Biotechnology

Phase

Source record

Phase I

Modality

AI-normalized

small molecule

Target

AI-normalized

F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)

Indication / condition

AI-normalized

Neutropenia

Intervention

Source record

F-627, EC regimen

Source & freshness

Source record

NCT ID

NCT02527746

Original source

ClinicalTrials.gov

Source last updated

Feb 23, 2024

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02527746

Title

A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast Cancer

Sponsor

EVIVE Biotechnology

Status

COMPLETED

Phase

Phase I

Condition raw

Neutropenia

Condition normalized

Neutropenia

Modality raw

Neutropenia

Modality normalized

small molecule

Target raw

F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)

Target normalized

F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)

Interventions

F-627, EC regimen

Public preview

Source record

This clinical trial evaluated the safety and pharmacokinetics of F-627 as an adjuvant to chemotherapy in female breast cancer patients undergoing myelotoxic chemotherapy. The study was conducted by EVIVE Biotechnology in collaboration with Fudan University, involving 18 patients across three dose cohorts.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Single-Center, Open-Label, Dose-Escalation Phase I Clinical Trial of Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein for Injection as an Adjuvant to Chemotherapy in Subjects With Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02527746

Status

COMPLETED

Phase

Phase I

Sponsor

EVIVE Biotechnology

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the safety and pharmacokinetics of F-627 as an adjuvant to chemotherapy in female breast cancer patients undergoing myelotoxic chemotherapy. The study was conducted by EVIVE Biotechnology in collaboration with Fudan University, involving 18 patients across three dose cohorts.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 23, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02527746

Indication

Neutropenia

Modality

small molecule

Target

F-627 (Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein)

Intervention

F-627, EC regimen

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.